Genolution

Genolution Net Debt

The Net Debt of Genolution (225220.KQ) as of Oct 22, 2026 is -9.14 B KRW. In the previous year, Net Debt was -18.68 B KRW — a change of -51.09% (higher).

Net Debt

-9.14 BKRW

YoY

-51.09%

Last updated:

Net Debt of Genolution is 2024 -9.14 B KRW. Net Debt of Genolution was 2023 -18.68 B KRW. It decreases by -51.09% higher compared to the previous year.

The Genolution Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2017
-2.15 B KRW
Jan 1, 2018
-3.57 B KRW
Jan 1, 2019
-265.64 M KRW
Jan 1, 2020
-42.31 B KRW
Jan 1, 2021
-45.94 B KRW
Jan 1, 2022
-31.32 B KRW
Jan 1, 2023
-18.68 B KRW
Jan 1, 2024
-9.14 B KRW
The Genolution Net Debt history
YEARNet DebtYoY
-9.14 BKRW-51.09%
-18.68 BKRW-40.35%
-31.32 BKRW-31.82%
-45.94 BKRW+8.57%
-42.31 BKRW+15,827.76%
-265.64 MKRW-92.56%
-3.57 BKRW+65.85%
-2.15 BKRW-7.48%
-2.33 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Net Debt of Genolution is -9.14 B KRW in 2024.

Net Debt of Genolution changed from -18.68 B KRW to -9.14 B KRW, representing a -51.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Genolution since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Genolution historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Genolution

All Key Metrics — Genolution